Urgent.News

What's breaking now, across hundreds of outlets.

Finance & Markets

Ginkgo Bioworks CFO Steven Coen sells $36,045 in stock

Ginkgo Bioworks CFO Steven Coen sells $36,045 in stock

Ginkgo Bioworks CFO Steven Coen sold 2,403 shares of the company's Class A Common Stock on October 5, 2026, for a total of $36,045. The sales were executed in line with a pre-approved sales plan aimed at adhering to Rule 10b5-1 under the Securities Exchange Act of 1934. Currently trading at $11.47, the stock price is significantly lower than the $15.00 per share at which Coen sold his shares.

This transaction reduces Coen's beneficial ownership in Ginkgo Bioworks Holdings, Inc. to 49,448 shares. For those interested in a more detailed analysis, a Pro Research Report on the company can be accessed among the nearly 1,400 US equities covered by the service. Ginkgo Bioworks reported its Q2 2026 financial results, with revenue falling to $20 million, down from the previously forecasted $29.9 million, marking a 48% decrease year-over-year.

Despite this decline, the company reported an adjusted loss of $0.92 per share, better than the expected $1.05 loss. Ginkgo remains committed to advancing its autonomous labs, including the expanded Nebula system in Boston, and has $389 million in total liquidity on hand. Analysts have expressed concerns about the company's growth trajectory, with TD Cowen downgrading the stock to Hold and lowering its price target to $9.00, while BTIG maintained a Sell rating and reduced its price target further to $5.00.

The company is navigating a transitional phase, with a focus on building out its Autonomous Labs by 2026, a process that will require substantial capital and time.

Rewritten by urgent.news; may contain errors — check the original.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at investing.com →

Report a problem with this story